EBV viremia and post-transplantation lymphoproliferative disorders (PTLDs) have been associated with high mortality rates after allogeneic hematopoietic SCT (allo-HSCT). Few retrospective studies, without EBV load monitoring postulated that umbilical cord blood transplantation (UCBT) might be associated with high incidence of EBV events. We retrospectively studied 175 UCBT recipients for whom RQ-PCR was used to monitor EBV blood load at least once a week during the first 3 months after UCBT. Median age was 23 years, 74% had leukemia. Conditioning was myeloablative in 54% and reduced intensity conditioning (RIC) was used in 46%. A total of 24 patients presented an EBV reactivation. For 15 patients, the reactivation occurred during the first 100 days (cumulative incidence: 8%) and included 4 EBV-PTLD. Rituximab as preemptive treatment was used in 12 of these 15 patients. In univariate analysis, the increased risk of early EBV reactivation was associated with RIC in combination with antithymocyte globulin (P ¼ 0.03) and previous history of auto-HSCT (P ¼ 0.01). Multivariate analysis did not find any independent risk factor. EBV reactivation as time-dependent covariate was not statistically associated with survival. Therefore, EBV events were not major complications after UCBT when EBV load is weekly monitored and preemptive treatment started.
INTRODUCTION
EBV is a gamma herpes virus infecting over 90% of humans and persisting for the lifetime in healthy individuals. 1 Following hematopoietic SCT (HSCT), loss of cytotoxic T-cell surveillance may lead to the expansion of EBV-infected B cells, clinically translating from asymptomatic viremia to EBV-related posttransplantation lymphoproliferative disorder (EBV-PTLD). All studies that have investigated EBV events (reactivation and disease) after HSCT, beyond the primary EBV infection, 2 found risk factors such as: use of TBI in conditioning, 3 antithymocyte globulin (ATG), unrelated donor and HLA mismatch, T-cell depletion and occurrence of acute or chronic GVHD. 4 Unrelated umbilical cord blood transplantation (UCBT) has been used as an alternative stem cell source. The cord blood graft has specific immunological characteristics not only because of a low number of infused donor T cells, but also because of functional immaturity of these naive T cells in the early post-transplant period that impairs T-cell cytotoxicity. 5 The ability of cord blood-naive T cells to regulate EBV reactivation is uncertain, and the incidence of EBV viremia and EBV-PTLD have to be assessed in UCBT recipients. Three studies have been published on the subject, [6] [7] [8] and none of them performed systematic EBV RQ-PCR monitoring. The aim of this retrospective multicenter study was to investigate the incidence and risk factors of EBV events after UCBT. The second objective was to study the role of systematic monitoring and preemptive therapy on preventing severe complications of EBV infection.
PATIENTS AND METHODS

Data collection and study design
This study used data from the Eurocord database from four French transplant centers with laboratories equipped to perform RQ-PCR for EBV monitoring, which was conducted at least once a week during the first 100 days post UCBT and thereafter when clinically indicated. Data related to EBV were collected in a specific clinical form, completed by transplant centers, checked by a Eurocord medical coordinator and entered into the database after validation.
Patients received UCBT after myeloablative (MAC) or reduced intensity (RIC) conditioning regimen. MAC was defined as a regimen using total oral BU at a dose X8 mg/kg or intravenously 46.4 mg/kg or using TBI dose 46 Gy.
Definition of EBV events and PCR methodology
EBV events were defined according to the last European Conference on Infection in Leukemia. 9 EBV viremia was defined as detection and quantification of EBV DNA in peripheral blood according to each transplant center RQ-PCR threshold. EBV-PTLD was classified as probable when there was a significant organ disease with high EBV blood load, and proven when PTLD with EBV was detected from an organ biopsy.
To quantify EBV blood load, RQ-PCR was used with different methods according to the four transplant centers participating in the study. Briefly, at University Hospital of Bordeaux (Bordeaux), nucleic acid was extracted from whole blood using the Roche MagNA Pure Total Nucleic Acid Isolation kit (Roche Diagnostics, Indianapolis, IN, USA). The EBV viral load was then measured by RQ-PCR using primers that amplify the BXLF1 region of the EBV genome. At Hospital E Herriot (Lyon) and University Hospital of Clermont-Ferrand (Clermont-Ferrand), the EBV R-gene Quantification kit (Argene, Varilhes, France) was used as an in vitro nucleic acid amplification test for the quantification of EBV DNA in whole blood using primers that amplify BXLF1 too. At Saint Louis Hospital (Paris), until April 2004, EBV viremia was monitored using real-time TaqMan RQ-PCR, viral DNA was extracted from 2-3 Â 10 6 PBMC or 200 mL of plasma using QIAamp Blood Minikit (Qiagen, Courtaboeuf, France). EBV blood load was then determined using primers that amplify the BALF5 region of EBV genome. From April 2004 up to date, the EBV R-gene Quantification kit (Argene) is used as an in vitro nucleic acid amplification test for the quantification of EBV DNA in the whole blood.
Outcomes definitions and statistical methods
Neutrophil engraftment was defined as the first of three consecutive days with neutrophil counts 40.5 Â 10 9 /L. Graft failure was defined as the absence of hematopoietic recovery at day þ 60, second transplantation or autologous reconstitution. Full donor chimerism was defined as the presence of more than 95% of donor cells. Acute GVHD (aGVHD) was diagnosed and graded according to Glucksberg criteria. 10 OS was defined as the time between the date of transplantation and the date of death from any cause or the date of the last follow-up for survivors.
A cumulative incidence (CI) function, with death as competing event, was used to estimate EBV reactivation, neutrophil recovery, occurrence of aGVHD and TRM. The Kaplan-Meier method was used to estimate OS. Multivariate models for risk factor analysis were performed using the Fine and Gray method. These models were constructed using a forward selection procedure and only variables that attained a P-value of 0.15 in univariate analysis were entered into the final model. Covariates considered were age, history of previous auto-HSCT, recipient CMV and EBV serostatus, recipient gender, median number of nucleated cells infused, median number of CD34 þ cells infused, intensity of conditioning regimen (RIC or MAC), use of TBI, fludarabine or BU in conditioning regimen, use of ATG, number of UCB units (single vs double), HLA disparity and mismatch of EBV recipient serological status with maternal serology. To detect the differences between patients with or without EBV reactivation, the above variables were compared using Mann-Whitney test for continuous variables and Chi-square test or Fisher's test for categories. EBV reactivation was analyzed as time-dependent covariate in a Cox model for OS.
Statistical analyses were performed with SPSS 18.0 statistical software (SPSS, Chicago, IL, USA), and Splus 6.1 (Math Soft, Seattle, WA, USA). Table 1 . Among 23 patients with nonmalignant diseases, there were 16 Fanconi anemias and 1 nocturnal paroxysmal hemoglobinuria. Ninety-five patients received MAC and 78 patients received RIC. aGVHD prophylaxis consisted mainly of a combination of CY with mycophenolate mofetil (50.3%) or prednisone (30.2%). ATG was given before transplant in 85 patients.
RESULTS
Patients
Ninety-eight patients received a single UCBT and 77 a double UCBT. Donor-recipient HLA compatibility was determined by Aglevel typing for HLA-A and HLA-B and by allele-level typing for HLA DRB1. Most patients received a 1-2 HLA-mismatch UCBT.
EBV serology was unavailable for nine patients (5.2%), whereas 88% of tested patients were seropositive for EBV in the pretransplant period. Patients received aciclovir, valaciclovir or maribavir (one patient) viral prophylaxis. Dates of injections and doses were not part of the updated data for this study. In addition, pediatric patients received i.v. Ig. Supportive care varied according to the transplant centers.
Early and late outcomes Neutrophil engraftment occurred at a median of 24 days (range 5-64 days) with CI of neutrophil recovery at day þ 60 of 77 ± 3%. Number of CD34 þ cell dose infused (41.7 Â 10 5 /kg) was associated with greater neutrophil recovery (P ¼ 0.014). The CI of grade II-IV aGVHD was 36 ± 4% and 21 patients developed aGVHD grade III-IV. Double UCBT was associated with higher incidence of aGVHD (45% vs 28% in single UCBT, P ¼ 0.008). CI of chronic GVHD at 2 years was 28%, 50 patients developed chronic GVHD, 29 were limited and 21 extensive.
With a median follow-up of 26 months (2.5 months to 7.2 years) after UCBT, OS at 2 years was 47±4%. OS for patients with nonmalignant disorders was 44% and it was 48% for malignant disorders. In this series, patient-, disease-, graft-and transplantation-related factors analyzed were not associated with improved survival.
Ninety-one patients died; 33% of patients died of relapse or disease progression and 67% of transplant-related complications, of which 14 were attributed to acute or chronic GVHD and 22 to infectious causes, including 3 EBV-PTLD.
Incidence and risk factors for EBV reactivation A total of 24 EBV reactivations among 175 patients have been observed after a median of 86 days (14 days to 2.7 years), 1 patient out of the 24 was EBV seronegative before transplant. For 15 patients, EBV reactivation occurred during the first 100 days after UCBT, whereas 9 patients presented an EBV reactivation after this period. CI of EBV reactivation was 8 ± 2% at 100 days and 12 ± 4% at 1 year after UCBT.
Among patient-, disease-and transplantation-related factors, patients who experienced EBV reactivation (n ¼ 24) differed from those who did not (n ¼ 151) for the history of previous autologous transplantation and the number of total nucleated cells (TNC) infused: among patients who had EBV reactivation, 29% had a previous history of auto-SCT vs 10% in non-EBV reactivation group (P ¼ 0.01). Similarly, median TNC was 2.6 Â 10 7 /kg in EBV reactivation group vs 3.2 Â 10 7 /kg in non-EBV reactivation group (P ¼ 0.04).
In a univariate analysis, factors associated with CI of EBV viremia at 100 days were age 418 years (P ¼ 0.008), history of previous auto-HSCT (P ¼ 0.01) and use of ATG as part of RIC regimen (P ¼ 0.03) ( Table 2 and Figure 1 ). Multivariate analysis did not identify independent risk factors associated with an increased risk of EBV viremia at day 100.
The influence of EBV reactivation on OS and TRM was analyzed as a time-dependent covariate and did not show any statistically significant difference (P ¼ 0.10 and P ¼ 0.19, respectively).
Preemptive treatment For the 15 patients who had EBV reactivation in the first 100 days of transplantation, 12 (80%) received anti-CD20 MoAb after a median of 16 days after the first positive RQ-PCR. For the remainder nine patients who had an EBV reactivation after day þ 100, two received rituximab after first positive RQ-PCR.
EBV-PTLD Four cases of EBV-PTLD (one probable and three proven) were identified, and the CI was 2±1% at 2 years. Diagnosis of EBV-PTLD occurred in a median time of 73 days (range 63-80 days) after UCBT and median of 28 days after first positive RQ-PCR (range 17-55 days). Three patients had a disseminated disease. EBV-PTLD pathology showed either monoclonal (n ¼ 2) or polyclonal (n ¼ 1) B cells.
DISCUSSION
In this retrospective, multicentric study on 175 UCBT recipients, we observed a CI of EBV viremia at 100 days and 1 year of 8 ± 2% and 12±4%, respectively. The first CI is more representative of asymptomatic reactivations because of systematic monitoring at this period of accrual. We also found four cases of EBV-PTLD (CI 2±1% at 2 years) diagnosed after a median time of 73 days post transplantation and 28 days after the first positive RQ-PCR. There was no association of EBV reactivation and OS or TRM.
The RQ-PCR threshold for diagnosis of EBV viremia is currently an unavoidable bias in all multicentric studies. Indeed, all RQ-PCR threshold values studied to define cutoff at risk for EBV-PTLD have been established by retrospective single-center experiences and have not been validated prospectively in other centers because of the heterogeneity of methods. In view of this bias heterogeneity in our study, we decided to consider the cutoff points of each center as a binary variable, presence or absence of reactivation according to each transplant center threshold and no quantitative analysis was performed. Also, patient selection criteria excluded any confounding bias in terms of intrinsic risk to present an EBV event.
The incidence of EBV viremia did not appear increased after unrelated UCBT. Previous studies with systematic monitoring of EBV blood load in post transplant period revealed a wide range from 8.8% in transplant with MAC regimen, 11 35% in transplants with RIC, 11 54% in the T-cell depletion HSCT, 12 and even 65% in some transplants with T-cell depletion and ATG. 13 Some of these studies, including those in UCBT, 6, 7 had patients with inherent risk of reactivation to EBV like SCID in their cohorts. Furthermore, these two studies in UCBT did not perform any systematic monitoring, leading to an underestimation of non-lymphoproliferative events, estimated at 4.5%. A recent French single-center study, including 33 UCBT only with RIC regimen, found an overall incidence of EBV reactivation about 5/33 (15%) and 2 EBV-PTLD. 8 Given our results, we could speculate that patients who underwent UCBT have a risk of EBV reactivation probably correlated to the circumstances of the graft in terms of conditioning and immunosuppression. Immaturity of UCB lymphocytes could have been responsible for higher susceptibility to EBV reactivation, as previously described for HHV6, 14 adenovirus 15 and VZV. 16 In light of the studies on the subject, including this one, it appears reasonable to suggest that patients transplanted with an unrelated UCB are not more susceptible to EBV events.
Importantly, the prompt start of preemptive treatment once EBV reactivation is detected with anti-CD20 seems to be an important tool for controlling the EBV load. This observation can explain the reason why EBV events do not impact TRM or survival. Although our data are limited due to the small number of patients we suggest that weekly EBV monitoring after UCBT might decrease the incidence of severe EBV complications.
